Alberts A W, Chen J, Kuron G, Hunt V, Huff J, Hoffman C, Rothrock J, Lopez M, Joshua H, Harris E, Patchett A, Monaghan R, Currie S, Stapley E, Albers-Schonberg G, Hensens O, Hirshfield J, Hoogsteen K, Liesch J, Springer J
Proc Natl Acad Sci U S A. 1980 Jul;77(7):3957-61. doi: 10.1073/pnas.77.7.3957.
Mevinolin, a fungal metabolite, was isolated from cultures of Aspergillus terreus. The structure and absolute configuration of mevinolini and its open acid form, mevinolinic acid, were determined by a combination of physical techniques. Mevinolin was shown to be 1,2,6,7,8,8a-hexahydro-beta, delta-dihydroxy-2,6-dimethyl-8-(2-methyl-1-oxobutoxy)-1-naphthalene-hepatanoic acid delta-lactone. Mevinolin in the hydroxy-acid form, mevinolinic acid, is a potent competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase [mevalonate: NADP+ oxidoreductase (CoA-acylating), EC 1.1.1.34]; its Ki of 0.6 nM can be compared to 1.4 nM for the hydroxy acid form of the previously described related inhibitor, ML-236B (compactin, 6-demethylmevinolin). In the rat, orally administered sodium mevinolinate was an active inhibitor of cholesterol synthesis in an acute assay (50% inhibitory dose = 46 microgram/kg). Furthermore, it was shown that mevinolin was an orally active cholesterol-lowering agent in the dog. Treatment of dogs for 3 weeks with mevinolin at 8 mg/kg per day resulted in a 29.3 +/- 2.5% lowering of plasma cholesterol.
美伐他汀是一种真菌代谢产物,从土曲霉培养物中分离得到。通过多种物理技术相结合的方法确定了美伐他汀及其开环酸形式美伐他汀酸的结构和绝对构型。美伐他汀被证明是1,2,6,7,8,8a-六氢-β,δ-二羟基-2,6-二甲基-8-(2-甲基-1-氧代丁氧基)-1-萘庚酸δ-内酯。羟基酸形式的美伐他汀,即美伐他汀酸,是3-羟基-3-甲基戊二酰辅酶A还原酶[mevalonate:NADP+氧化还原酶(辅酶A酰化),EC 1.1.1.34]的强效竞争性抑制剂;其Ki为0.6 nM,可与先前描述的相关抑制剂ML-236B(洛伐他汀,6-去甲基美伐他汀)的羟基酸形式的1.4 nM相比较。在大鼠中,口服美伐他汀钠在急性试验中是胆固醇合成的活性抑制剂(50%抑制剂量=46微克/千克)。此外,已证明美伐他汀在犬中是一种口服活性降胆固醇药物。以每天8毫克/千克的剂量用美伐他汀治疗犬3周,导致血浆胆固醇降低29.3±2.5%。